Why does high-dose D-mannose capsule filling require dry granulation before encapsulation?

High-dose hard-shell capsule products containing plant-derived D-mannose at 70–90% w/w of the filled granule mass present a direct fill-weight control problem on high-speed dosator and tamping-pin encapsulation machines when raw crystalline powder is used without particle modification; batch-to-batch shifts in the API particle-size distribution, commonly observed as Dv50 variation between 50–150 µm, produce powder flow instability that drives capsule fill-weight relative standard deviation above the USP <905> acceptance limit. The standard corrective sequence is dry granulation by roller compaction, using an intragranular blend of D-mannose at 70–90% w/w, microcrystalline cellulose at 5–15% w/w, crospovidone at 2–5% w/w, and a final external addition of sodium stearyl fumarate at 0.5–1.5% w/w. Roller compaction is typically operated at roll pressures of 4–8 kN/cm with a roll speed of 5–10 rpm, followed by screen milling through a 800–1000 µm sieve to obtain granule flow suitable for automatic capsule filling; the resulting granulate should exhibit a Hausner ratio below 1.25 and a Carr index below 20% before encapsulation. Capsule filling is executed on tamping-pin or dosator machines with a target fill weight of 600–800 mg into size 00 hard gelatin or HPMC capsules. Dissolution is controlled by USP <711>, content uniformity by USP <905>, and moisture is maintained at ≤0.8% by Karl Fischer titration under USP <921>. Terminal finished product types include 500 mg and 1000 mg D-mannose hard-shell capsules for oral urinary tract support protocols.

In direct-compression operations for recurrent uncomplicated cystitis products, plant-derived D-mannose obtained from birch-wood hemicellulose hydrolysis is formulated as the primary active monosaccharide at 60–85% w/w of the core tablet mass. A representative compression blend contains microcrystalline cellulose at 10–20% w/w, croscarmellose sodium at 2–4% w/w as disintegrant, colloidal anhydrous silica at 0.5–1.0% w/w to reduce segregation, and magnesium stearate at 0.5–1.5% w/w introduced in a final lubrication step. Because the extracted crystalline material can exhibit an angle of repose above 40°, production-scale tablet presses are equipped with force feeders and operate at 15–25 kN compression force to achieve tablet hardness in the range of 100–180 N; friability is controlled below 1.0% under USP <1216> and disintegration is specified at not more than 15 min under USP <701>. Lubricant over-addition above 1.5% w/w is avoided because it can retard disintegration and dissolution; magnesium stearate is screened through a 500 µm sieve and blended for 3–5 min to limit hydrophobic film formation on the monosaccharide particles. Pre-drying of the API at 40–50°C to a loss on drying of ≤0.5% is applied when compression suites exceed 55% relative humidity. Compliance for elemental impurities follows ICH Q3D and USP <232>/<233>, while residual solvents are aligned with ICH Q3C. Unit-dose weight variation is verified by USP <905>. Terminal finished product types include 500 mg and 1000 mg film-coated tablets for adult oral administration.

Single-dose stick-pack granulation lines processing plant-derived D-mannose at high API load require aqueous fluid-bed granulation because the crystalline monosaccharide has low compactibility and can segregate during sachet filling. The granulation formula contains D-mannose at 85–95% w/w, povidone K30 at 1–3% w/w as binder, citric acid anhydrous at 1–2% w/w for acid-stable reconstitution, and colloidal silicon dioxide at 0.5–1.0% w/w. Spray granulation is performed in a top-spray fluid-bed processor with inlet air temperature of 50–60°C, product temperature of 30–35°C, and atomising air pressure of 1.0–1.5 bar; final moisture is controlled to ≤0.8% by Karl Fischer titration under USP <921>. The dried granulate is sieved to a particle-size band of 250–1000 µm, with fines below 150 µm limited to ≤15% to maintain acceptable flow on auger-type sachet fillers. Fill-weight relative standard deviation is held at ≤1.5%, and seal integrity is verified on-line by vacuum decay or dye-penetration methods aligned with ASTM F88 and ASTM F2096. Compliance includes Ph. Eur. 2.9.12 for particle-size distribution, Ph. Eur. 2.9.3 for dissolution of oral powders, ICH Q3D, and ICH Q3C. Terminal finished product types include 1 g and 2 g single-dose stick packs for oral solution or direct oral administration.

When D-mannose is compounded as a sterile isotonic infusion, terminal sterilisation boundaries shift

Compounding of low-endotoxin plant-derived D-mannose into parenteral solutions is performed at 5% w/v in Water for Injection; the calculated osmolality of 270–290 mOsm/kg is approximately isotonic with plasma, making the solution suitable for intravenous infusion from an osmotic-pressure standpoint. Clarification and sterilising filtration use 0.22 µm PVDF or PES membrane filters, and aseptic filling is executed under EU GMP Annex 1 conditions with continuous particle monitoring. Terminal steam sterilisation at 121°C for 15 min is evaluated only as a secondary option because carbohydrate solutions may develop pH drift and colour-forming degradation products; a pH shift greater than 0.5 pH units during hold-time studies signals the need for aseptic filtration instead of terminal sterilisation. Sterility is verified by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14 using a dose-specific K/M limit, and sub-visible particulate matter by Ph. Eur. 2.9.19. Filter integrity is confirmed by bubble point or diffusion testing according to ISO 13408-1. Published data for specific injectable commercial configurations is limited; the operating boundaries above are derived from general parenteral carbohydrate solution handling rather than a marketed D-mannose infusion product. Terminal finished product types include 100 mL IV infusion containers and 50 mL syringe infusion preparations for hospital pharmacy use.

Combination effervescent granules containing D-mannose and potassium citrate require dry granulation because the acidic and carbonate effervescent partners react in the presence of moisture. A representative dry granulation formula contains D-mannose at 30–50% w/w, potassium citrate monohydrate at 20–40% w/w, sodium bicarbonate at 10–20% w/w, and citric acid anhydrous at 10–20% w/w. The mixture is roller-compacted and milled to 500–1000 µm, then lubricated externally with PEG 6000 at 1–3% w/w. Compression of effervescent tablets is performed at 20–40 kN to maintain low friability and rapid disintegration; disintegration is specified at not more than 3 min in 200 mL water at 20–25°C under USP <701>. Finished sachet products are filled under RH ≤30% and sealed in aluminium foil laminate to exclude atmospheric moisture. Compliance includes Ph. Eur. 2.9.1 for effervescent tablet disintegration, ICH Q3D, and USP <232>/<233>. Terminal product types include 4 g effervescent tablets and 5 g single-dose effervescent powder sachets for oral solution.

Low-Endotoxin Oral Powder for MPI-CDG Hospital Pharmacy Compounding

D-mannose is used in the management of phosphomannose isomerase deficiency (MPI-CDG), where oral administration protocols commonly reference 0.17 g/kg body weight every 6 h. Hospital pharmacy compounding of this product requires low-endotoxin API milled and sieved to 125–500 µm and filled into single-dose sachets at RH ≤30%. The formulation may be presented as 100% D-mannose oral powder or with up to 1% w/w colloidal silicon dioxide as a flow aid; the API assay is controlled at 98.0–102.0% on the dried basis by a validated liquid chromatographic method. Microbial quality is assessed by USP <61>/<62>, bacterial endotoxins by Ph. Eur. 2.6.14, and elemental impurities by ICH Q3D. Manufacturing under 21 CFR 211 requires line clearance and validated cleaning as per 21 CFR 211.67. Terminal product types include 1 g, 2 g, and 5 g oral powder sachets for reconstitution in water or direct administration.